By NewsDesk  @infectiousdiseasenews In late December 2019, antibiotic development and commercialization company, Melinta Therapeutics, Inc. initiated a voluntary Chapter 11 process to effectuate restructuring...

The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults....

The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular...

The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic...

This week, the U.S. Department of Health and Human Services (HHS) issued the first Project BioShield contract to fund the advanced development needed to support the expanded use of an existing antibiotic...

Staphylococcus aureus is a major human pathogen prone to developing antibiotic resistance, causing 120,000 cases of bloodstream infections every year in the United States and over 5000 in Australia; the...

Once rare, the superbug methicillin-resistant Staphylococcus aureus (MRSA) infects hundreds of thousands of people in the U.S. each year and kills about 20,000. Antibiotic overuse has made MRSA more common...

Viral hepatitis is a disease that causes inflammation of the liver. There are three viruses responsible for most cases of the disease: hepatitis A, B, and C. Hepatitis A is typically caused by consuming...

The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including...

Tychan‘s first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF), called TY014, has successfully completed Phase 1A/1B safety trials in Singapore, it announced today. Tychan...